文献リスト

1) 厚生労働省エイズ動向委員会. 平成20(2008)年エイズ発生動向-概要-. 平成20(2008)年エイズ発生動向年報. 平成21年6月17日

2) Yoritaka A, Ohta K, Kishida S. Prevalence of neurological complications in Japanese patients with AIDS after the introduction of HAART. Rinsho Shinkeigaku. 2007; 47: 491-6

3) Nakagawa M, Izumo S, Kishida S. The state and issue of NeuroAIDS in Japan. Neuroimmunology. 2007; 15: 203-7

4) Zolopa A, Andersen J, Powderly W, et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS One. 2009; 4: e5575

5) Hammer SM, Eron JJ Jr, Reiss P, et al. Antiretro­viral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA. 2008; 300: 555-70

6) McArthur JC, Brew BJ, Nath A. Neurological complications of HIV infection. Lancet Neurol. 2005; 4: 543-55

7) Berenguer J, Miralles P, Arrizabalaga J, et al. Clinical course and prognostic factors of pro­gressive multifocal leukoencephalopathy in patients treated with highly active antiretroviral therapy. Clin Infect Dis. 2003; 36: 1047-52

8) Wyen C, Hoffmann C, Schmeisser N, et al. Progressive multifocal leukencephalopathy in patients on highly active antiretroviral therapy: survival and risk factors of death. J Acquir Immune Defic Syndr. 2004; 37: 1263-8

9) Vendrely A, Bienvenu B, Gasnault J, et al. Fulminant inflammatory leukoencephalopathy associated with HAART-induced immune restora­tion in AIDS-related progressive multifocal leukoencephalopathy. Acta Neuropathol. 2005; 109: 449-55

10) Letendre S, Marquie-Beck J, Capparelli E, et al. Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol. 2008; 65: 65-70

11) Smit TK, Brew BJ, Tourtellotte W, et al. Indepen­dent evolution of human immuno­deficiency virus (HIV) drug resistance mutations in diverse areas of the brain in HIV-infected patients, with and without dementia, on antiretroviral treatment. J Virol. 2004; 78: 10133-48

12) Nath A, Sacktor N. Influence of highly active antiretroviral therapy on persistence of HIV in the central nervous system. Curr Opin Neurol. 2006; 19: 358-61

13) Varatharajan L, Thomas SA. The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommen­dations for further research. Antiviral Res. 2009; 82: A99-109

14) Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocogni­tive disorders. Neurology. 2007; 69: 1789-99

15) Crews L, Patrick C, Achim CL, et al. Molecular Pathology of Neuro-AIDS (CNS-HIV). Int J Mol Sci. 2009; 10: 1045-63

16) Woods SP, Moore DJ, Weber E, et al. Cognitive neuropsychology of HIV-associated neuro­cognitive disorders. Neuropsychol Rev. 2009; 19: 152-68

17) Cysique LA, Vaida F, Letendre S, et al. Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy. Neuro­logy. 2009; 73: 342-8

18) Boissé L, Gill MJ, Power C. HIV infection of the central nervous system: clinical features and neuropathogenesis. Neurol Clin. 2008; 26: 799-819

19) Eggers C, Hertogs K, Stürenburg HJ, et al. Delayed central nervous system virus suppression during highly active antiretroviral therapy is associated with HIV encephalopathy, but not with viral drug resistance or poor central nervous system drug penetration. AIDS. 2003; 17: 1897-906

20) Robertson KR, Robertson WT, Ford S, et al. Highly active antiretroviral therapy improves neurocognitive functioning. J Acquir Immune Defic Syndr. 2004; 36: 562-6

21) Wright E, Brew B, Arayawichanont A, et al. Neurologic disorders are prevalent in HIV-positive outpatients in the Asia-Pacific region. Neurology. 2008; 71: 50-6

22) Cysique LA, Maruff P, Brew BJ. Antiretroviral therapy in HIV infection: are neurologically active drugs important？ Arch Neurol. 2004; 61: 1699-704

23) Letendre SL, McCutchan JA, Childers ME, et al. Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders. Ann Neurol. 2004; 56: 416-23

24) Robertson K, Kopnisky K, Hakim J, et al. Second assessment of NeuroAIDS in Africa. J Neurovirol. 2008; 14: 89-101

25) Murdoch DM, Venter WD, Van Rie A, et al. Immune reconstitution inflammatory syndrome (IRIS): review of common infectious manifesta­tions and treatment options. AIDS Res Ther. 2007; 4: 9

26) Pepper DJ, Marais S, Maartens G, et al. Neuro­logic manifestations of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome: a case series. Clin Infect Dis. 2009; 48: e96-107

27) Pfeffer G, Prout A, Hooge J, et al. Biopsy-proven immune reconstitution syndrome in a patient with AIDS and cerebral toxoplasmosis. Neuro­logy. 2009; 73: 321-2

28) Shelburne SA 3rd, Hamill RJ, Rodriguez-Barradas MC, et al. Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medi­cine(Baltimore). 2002; 81: 213-27

29) Robertson J, Meier M, Wall J, et al. Immune re­constitution syndrome in HIV: validating a case definition and identifying clinical predictors in persons initiating antiretroviral therapy. Clin Infect Dis. 2006; 42: 1639-46

30) Riedel DJ, Pardo CA, McArthur J, et al. Therapy Insight: CNS manifestations of HIV-associated immune reconstitution inflammatory syndrome. Nat Clin Pract Neurol. 2006; 2: 557-65

31) Dhasmana DJ, Dheda K, Ravn P, et al. Immune reconstitution inflammatory syndrome in HIV-infected patients receiving antiretroviral therapy: pathogenesis, clinical manifestations and manage­ment. Drugs. 2008; 68: 191-208

32) Dautremer J, Pacanowski J, Girard PM, et al. A new presentation of immune reconstitution inflammatory syndrome followed by a severe paradoxical reaction in an HIV-1-infected patient with tuberculous meningitis. AIDS. 2007; 21: 381-2

33) Shelburne SA 3rd, Darcourt J, White AC Jr, et al. The role of immune reconstitution inflammatory syndrome in AIDS-related Cryptococcus neofor­mans disease in the era of highly active antiretro­viral therapy. Clin Infect Dis. 2005; 40: 1049-52

34) Tan K, Roda R, Ostrow L, et al. PML-IRIS in patients with HIV infection: clinical manifes­tations and treatment with steroids. Neurology. 2009; 72: 1458-64

35) Carr A, Samaras K, Thorisdottir A, et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystro­phy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet. 1999; 353: 2093-9

36) Corral I, Quereda C, Moreno A, et al. Cerebrovas­cular ischemic events in HIV-1-infected patients receiving highly active antiretroviral therapy: incidence and risk factors. Cerebrovasc Dis. 2009; 27: 559-63

37) Cole JW, Pinto AN, Hebel JR, et al. Acquired immunodeficiency syndrome and the risk of stroke. Stroke. 2004; 35: 51-6

38) d'Arminio A, Sabin CA, Phillips AN, et al. Cardio- and cerebrovascular events in HIV-infected persons. AIDS. 2004; 18: 1811-7

39) Bozzette SA, Ake CF, Tam HK, et al. Cardio­vascular and cerebrovascular events in patients treated for human immunodeficiency virus infec­tion. N Engl J Med. 2003; 348: 702-10

40) Ortiz G, Koch S, Romano JG, et al. Mechanisms of ischemic stroke in HIV-infected patients. Neurology. 2007; 68: 1257-61

41) 平成20年度厚生労働科学研究費補助金エイズ対策研究事業 服薬アドヒアランスの向上・維持に関する研究班. 抗HIV治療ガイドライン. 2009

42) Abrams DI, Goldman AI, Launer C, et al. A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with human immunodeficiency virus infection. The Terry Beirn Community Programs for Clinical Research on AIDS. N Engl J Med. 1994; 330: 657-62

43) Cherry CL, Affandi JS, Imran D, et al. Age and height predict neuropathy risk in patients with HIV prescribed stavudine. Neurology. 2009; 73: 315-20

44) Simpson DM, Brown S, Tobias J, et al. Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy. Neurology. 2008; 70: 2305-13

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp